Key facts
- Preveta’s last known valuation is $25.0M (Dec 2022).
- It has raised $10.7M across 1 recorded rounds; the latest was Early Stage VC ($6.3M) in Dec 2022.
- Notable investors include Techstars, Microsoft for Startups, MaC Venture Capital, Sovereign's Capital, Bullpen Capital — 9 tracked in total.
- Preveta has filed 1 Form D with the SEC, most recently Jan 2023 ($6.3M sold to 7 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Preveta
Funding rounds
1 roundsAbout Preveta
Developer of a medical care coordination platform designed to transform cancer care by arming clinicians with data and insights to improve outcomes. The company's platform utilizes artificial intelligence and analytical engines to provide clinicians and healthcare organizations with care navigation services, enabling medical professionals to improve patient treatment experience and leverage these patient interactions to gather deeper insights about them.
- Sector
- Healthcare
- HQ
- Redondo Beach, CA, United States
- Founded
- 2018
- Employees
- 22
- Website
- preveta.com/
- Ownership
- Privately Held (backing)
Preveta doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Preveta shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Preveta in its N-PORT filings yet. We sweep new filings monthly.